Genentech Biooncology
Genentech Biooncology
    • Home 

    • Research Education 

    • Research HDIs 

    • The structure of HER2 

    • GLOSSARY
    • ON
    • OFF
  • Print
  • share
 
 
' The related resources bookmark allows you to jump directly to other pages on the site that contain information directly related to the topics you're currently exploring.
  • Home Page
  • What's New?
  • Tumor Types
  • Molecular Causes of Cancer
  • Biological Pathways
  • Therapeutic Targets
  • Pipeline Molecules
  • Research Education
    • Research ADCs
    • Research Apoptosis
    • Research B cell
    • Research BRAF
    • Research Cancer Immunotherapy
    • Research HDIs
      • HER2+ breast cancer
      • HER2 dimerization
      • What makes HER2 different?
      • The structure of HER2
      • The HER2:HER3 dimer
      • Inhibition of HER2 dimerization
      • Slide decks and videos
      • References
      • Glossary
    • Research HER Pathways
    • Research MET
    • Research VEGF
  • Clinical Trials
  • Resources
  • Contact Us
Register for Updates Unsubscribe Share
Register for Updates Unsubscribe Share

Related Resources for this page:

  • Tumor Types
    • Breast Cancer
  • Molecular Causes of Cancer
    • Evading growth suppressors
    • Activating invasion and metastasis
    • Enabling replicative immortality
    • Resisting cell death
  • Biological Pathways
    • HER Signaling
    • MAPK Signaling
  • Therapeutic Targets
    • HER1
    • HER2
    • HER3
    • HER4
  • Future Directions
    • Antibody-Drug conjugates
      • HER Signaling
      • Receptor-Mediated Endocytosis
      • Anti-HER3/EGFR MAb (MEHD7945A)
      • Anti-PDL1 (MPDL3280A)
      • Cytotoxic agent
      • What are ADCs?
      • Stable linker
      • Monoclonal antibody
      • Current research in ADCs
      • Targeting cancers with ADCs
      • Glossary
      • A brief history of ADCs
      • How are ADCs designed to work?
      • Research ADCs
      • Multimedia Resources
      • HER2:HER3 dimer
      • Glossary
      • HER1/EGFR evaluation
      • HER1/EGFR in lung cancer
      • HER1/EGFR in pancreatic cancer
      • HER1/EGFR and prognosis
      • Summary
      • HER1/EGFR as a therapeutic target
      • HER2 in breast cancer
      • HER2 detection methods
      • HER2 dysregulation
      • HER2
      • HER2 in ovarian cancer
      • HER2 and prognosis
      • Summary
      • HER2 as a therapeutic target
      • HER3 in breast cancer
      • HER3 dysregulation
      • HER3 evaluation
      • HER3
      • HER3 in ovarian cancer
      • Summary
      • HER3 as a therapeutic target
      • HER4
      • HER pathways slide decks and videos
      • Receptor activation
      • Cancer effects
      • Dimerization
      • Overview
      • HER ligands
      • HER receptors
      • Summary
      • Therapeutic potential of HER pathways
      • Research MET
      • What is Met?
    • Glycoengineered Antibodies
      • HER Signaling
      • Anti-HER3/EGFR MAb (MEHD7945A)
    • Non-Antibody Biologics
      • Apoptosis
      • What are the strategies for inhibiting the VEGF pathway?
    • Targeted Small Molecules
      • Apoptosis
      • MAPK Signaling
      • PI3K/Akt/mTOR Signaling
      • Anti-HER3/EGFR MAb (MEHD7945A)
      • MEK Inhibitor (GDC-0973)
      • PI3K Inhibitor (GDC-0941)
      • Glossary
      • Resisting apoptosis
      • HER2:HER3 dimer
      • Glossary
      • HER1/EGFR evaluation
      • HER1/EGFR in lung cancer
      • HER1/EGFR in pancreatic cancer
      • HER1/EGFR and prognosis
      • Summary
      • HER1/EGFR as a therapeutic target
      • HER2 in breast cancer
      • HER2 detection methods
      • HER2 dysregulation
      • HER2
      • HER2 in ovarian cancer
      • HER2 and prognosis
      • Summary
      • HER2 as a therapeutic target
      • HER3 in breast cancer
      • HER3 dysregulation
      • HER3 evaluation
      • HER3
      • HER3 in ovarian cancer
      • Summary
      • HER3 as a therapeutic target
      • HER4
      • HER pathways slide decks and videos
      • Receptor activation
      • Cancer effects
      • Dimerization
      • Overview
      • HER ligands
      • HER receptors
      • Summary
      • Therapeutic potential of HER pathways
      • Research MET
      • What is Met?
      • Slide decks and videos
      • What are the strategies for inhibiting the VEGF pathway?
      • Gastric Cancer
    • Traditional Monoclonal Antibodies
      • Angiogenic Signaling
      • HER Signaling
      • Parsatuzumab (Anti-EGFL7)
      • Anti-HER3/EGFR MAb (MEHD7945A)
      • Anti-PDL1 (MPDL3280A)
      • HER2:HER3 dimer
      • Glossary
      • HER1/EGFR evaluation
      • HER1/EGFR in lung cancer
      • HER1/EGFR in pancreatic cancer
      • HER1/EGFR and prognosis
      • Summary
      • HER1/EGFR as a therapeutic target
      • HER2 in breast cancer
      • HER2 detection methods
      • HER2 dysregulation
      • HER2
      • HER2 in ovarian cancer
      • HER2 and prognosis
      • Summary
      • HER2 as a therapeutic target
      • HER3 in breast cancer
      • HER3 dysregulation
      • HER3 evaluation
      • HER3
      • HER3 in ovarian cancer
      • Summary
      • HER3 as a therapeutic target
      • HER4
      • HER pathways slide decks and videos
      • Receptor activation
      • Cancer effects
      • Dimerization
      • Overview
      • HER ligands
      • HER receptors
      • Summary
      • Therapeutic potential of HER pathways
      • Research MET
      • What is Met?
      • Glossary
      • Slide decks and videos
      • What are the strategies for inhibiting the VEGF pathway?
      • Gastric Cancer

Dimerization Video

The Potential Role of Dimerization in HER2+ Breast Cancer Slide Deck

Potential Role of Dimerization


HER2+ Breast Cancer Slide Decks

HER2+ Breast Cancer Slide Decks

Comprehensive overview of HER2 Dimerization Inhibitors (HDIs)


New: HER2 Dimerization iTunes app

New: HER2 Dimerization iTunes app

Explore the potential of HER2 dimerization inhibition

View all downloadable resources
Share

The structure of HER2: domains and dimerization

HER2 contains extracellular, transmembrane, and intracellular domains. While the intracellular domain is responsible for phosphorylation and recruitment of proteins, the extracellular domain is where signal transduction is initiated through dimerization with other receptors.13 Preclinical research continues to uncover the individual roles of each sub-domain in receptor activation and signaling.

  • Select one to reveal more about HER2
  • 1Sub-domain I
  • Extracellular sub-domain I and sub-domain III

    Unlike other receptors in the HER family, sub-domain I on HER2 is constantly in contact with sub-domain III. Permanent interaction between these 2 sub-domains keeps the receptor in an open conformation, exposing sub-domain II, and ensuring the receptor is always ready to dimerize.3

  • 2Sub-domain II
  • Extracellular sub-domain II

    Sub-domain II is the dimerization domain. This domain enables HER2 to bind with other receptors in the HER family to initiate downstream signaling.3

  • 3Sub-domain III
  • Extracellular sub-domain I and sub-domain III

    Unlike other receptors in the HER family, sub-domain I on HER2 is constantly in contact with sub-domain III. Permanent interaction between these 2 sub-domains keeps the receptor in an open conformation, exposing sub-domain II, and ensuring the receptor is always ready to dimerize.3

  • 4Sub-domain IV
  • Extracellular sub-domain IV

    While the exact role of sub-domain IV in HER functioning is still unknown, it is believed to stabilize and lock the receptor in an open conformation. Other approaches to targeting HER2 bind to sub-domain IV to interfere with HER2 signaling, but sub-domain IV is not directly involved with dimerization. 13

  • 5Transmembrane Domain
  • Transmembrane domain

    The transmembrane domain of HER2 has been implicated in receptor activation control, but further research is required to understand its function in signaling initiation.13

  • 6Intracellular Domain
  • Intracellular domain

    The intracellular domain has a cytoplasmic linker, a tyrosine kinase component, and a tail that phosphorylates and recruits adapter proteins following dimerization.13 These adapter proteins can then initiate cell proliferation signaling, leading to cell growth, differentiation, and angiogenesis.12

  • Go back to all Domains
 
  • SITEMAP
  • /
  • PRIVACY POLICY
  • /
  • TERMS & CONDITIONS
  • /
  • CONTACT US
  • /
  • © 2013 Genentech USA, Inc. All rights reserved.
  • /
  • BIO0000574200
Next section: The HER2:HER3 dimer »

© 2011 Genentech USA, Inc. All rights reserved